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Abstract 
Background: Distal renal tubular acidosis (dRTA) is characterized by hyperchloremic 
metabolic acidosis, hypokalemia, hypercalciuria and nephrocalcinosis. It is due to reduced 
urinary acidification by the α-intercalated cells in the collecting duct and can be caused by 
mutations in ATP6V1B1, ATP6V0A4, or SLC4A1. Treatment with alkali is the mainstay of 
therapy.  
Patients and methods: This study presents clinical data on long-term follow-up of children 
with dRTA in a single centre, including genetic analysis.  
Results: Twenty-four children were included. Genetic diagnosis was confirmed in 19 patients: 
6 had mutations in ATP6V1B1, 10 in ATP6V0A4 and 3 in SLC4A1, 5 had no molecular 
diagnosis. There were 5 novel mutations (2 in ATP6V1B1 and 3 in ATP6V0A4). Two thirds of 
patients presented with features of proximal tubular dysfunction, leading to an erroneous 
diagnosis of renal Fanconi syndrome. The proximal tubulopathy disappeared after resolution 
of acidosis, indicating the importance of following proximal tubular function to establish the 
correct diagnosis. Growth retardation with a height below -2 SDS was found in 10 patients at 
presentation, but remained present in only 3 once established on alkali treatment. 
Sensorineural hearing loss was found in 5/6 patients with ATP6V1B1 mutations. Only 1 
patient with ATP6V0A4 mutations had sensorineural hearing loss during childhood. Nine 
children developed medullary cysts, but without apparent clinical consequences. Cyst 
development in this cohort was not correlated with age at therapy onset, molecular 
diagnosis, growth parameters or renal function.  
Conclusion: In general, the prognosis of dRTA is good in children treated with alkali. 
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Background 
Distal renal tubular acidosis (dRTA), also often referred to as type 1 RTA, is caused by a 
decreased capacity of the α-intercalated cells in the collecting duct to excrete protons. 
Biochemically, it is characterized by a hyperchloremic metabolic acidosis with normal plasma 
anion gap, hypokalemia and hypercalciuria with hypocitraturia causing nephrocalcinosis. 
Despite a profound metabolic acidosis, patients are unable to acidify their urine and will have 
a urinary pH >5.5 [1,2].  
Patients often present with vomiting, diarrhea or constipation, failure to thrive and/or rickets. 
Severe hypokalemia can cause muscle weakness or paralysis [2]. Chronic acidosis leads to 
bone demineralization which can result in rickets and/or stunted growth in children with 
dRTA. The excess of calcium that is released into the blood stream, combined with the 
decreased expression of renal calcium transporters in metabolic acidosis, causes 
hypercalciuria [3,4]. This hypercalciuria in turn can result in nephrocalcinosis, and if left 
untreated to renal calculi formation. Polyuria, due to impaired urinary concentrating ability 
(secondary nephrogenic diabetes insipidus) is another typical feature and may be related to 
electrolyte abnormalities in blood and/or urine and the nephrocalcinosis [5].  
To date, several genes are known to cause dRTA. Autosomal recessive inheritance is 
noted in mutations in ATP6V1B1, ATP6V0A4, and sometimes SLC4A1. Mutations in the 
latter gene, however, generally cause the autosomal dominant form of dRTA [1]. 
In this study we present data on children with dRTA followed in our outpatient clinic 
over the last 20 years, including the available data of DNA analysis. 
 
Patients and methods 
This is a single centre, retrospective study on the molecular diagnosis and clinical follow-up 
of children with dRTA, followed in the specialized tubulopathy outpatient clinic at Great 
Ormond Street Hospital (London, UK) in the last 20 years. Distal renal tubular acidosis was 
defined as hyperchloremic metabolic acidosis with a normal plasma anion gap, with 
inappropriately high urinary pH on repeated sampling. All parents of children with dRTA were 
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offered genetic analysis to confirm their diagnosis. Clinical and biochemical data were 
retrieved from the patients’ medical records and included details until transition into adult 
services. Estimated glomerular filtration rate (eGFR) was measured using the bedside 
Schwartz formula [6]. 
 
Results 
In total 24 patients were included, with a median follow-up of 10 years (range 1-18 years). 
Clinical details are presented in table 1. The molecular diagnosis was confirmed in 19/24 
patients. Six patients had homozygous or compound heterozygous mutations in ATP6V1B1, 
10 had mutations in ATP6V0A4 (including one pair of siblings) and 3 patients were found to 
have mutations in SLC4A1. We found 5 mutations not previously reported. These include 2 
mutations in ATP6V1B1 (c.905G>C; p.(Arg302Pro) in patient 2 and c.490_499del; 
p.(Ile164Alafs*8) in patient 6) and 3 mutations in ATP6V0A4 (c.1312_1315del; 
p.(Asp438Metfs*13) in patient 9, c.970del; p.(Glu324Argfs*22) in patient 11 and c.1238G>A; 
p.(Gly413Asp) in patient 15). In patient 20 only one mutation was found in ATP6V0A4. 
Although this mutation was predicted to be pathogenic, he was not considered as having a 
confirmed molecular diagnosis since mutations in this gene have an autosomal recessive 
pattern of inheritance. Patients 5 and 15 were seen in our clinic for a second opinion, 
treatment strategies may therefore not necessarily represent the general practice in our 
hospital.  
 
Disease presentation 
Age at diagnosis  
In general, patients with autosomal recessive mutations (patients 1-16 and patient 19) had a 
tendency to present earlier in life compared to patients with an autosomal dominant form of 
dRTA (patients 17 and 18). The children with autosomal recessive inherited mutations 
presented at a median age of 3 months (range 2 weeks – 2 years and 2 months), only 3 out 
of 17 children presented after the age of 1 year. In contrast, both children with autosomal 
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dominant mutations presented at after the age of 1 year, at 1 year and 5 months and 4 years, 
respectively (figure 1). This difference was statistically significant (p<0.01, student T-test). 
Interestingly, patient 17 was assessed initially at the age of 1 year because of the 
family history of dRTA in both mother and maternal grandmother. Molecular diagnosis was 
not available in the family at the time and the initial clinical assessment was unremarkable 
with normal plasma electrolytes (K+ = 4.3 mmol, HCO3 = 20 mmol/l), normal venous pH 
(7.34), normocalciuria (calcium/creatinine ratio of 0.36 mmol/mmol) and normal renal 
ultrasound. A diagnosis was not established at the time and only further observation 
recommended. At 17-months of age, she had an episode of diarrhea and subsequent blood 
tests revealed acidosis (venous pH 7.29, plasma HCO3 16 mmol/l), with inappropriately 
elevated urine pH (7.5), revealing her to be affected, later confirmed by molecular diagnosis. 
 
Presenting symptoms 
Many children with dRTA presented with failure to thrive and growth retardation. This was 
most profound in the children with ATP6V1B1 mutations and in those in whom no genetic 
mutation could be found (figure 2). Severe growth retardation according to the first 
documented measurement after presentation, with a height on or below -2 standard 
deviations scores (SDS), was found in a total of 12 children. It was documented in 4/6 
children with mutations in ATP6V1B1, in 3/10 children with mutations in ATP6V0A4, in 1/3 
with SLC4A1 and in 4/5 children without a confirmed genetic diagnosis.  
 All children were found to have metabolic acidosis at initial presentation, but given the 
retrospective nature of this study the exact blood pH at diagnosis could only be recovered in 
9 patients; all were <7.25. Serum bicarbonate levels at diagnosis, however, could be 
recovered in the majority of patients and were well below 18 mmol/L. Both blood pH and 
serum bicarbonate levels were the lowest in children with mutations in ATP6V0A4, children 
with mutations in SLC4A1 generally presented with less severe acidosis (figure 3).  
Two thirds of our patients presented with features of partial renal Fanconi syndrome. 
Fourteen children had tubular proteinuria, 8 children had a decreased tubular resorption of 
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phosphate (TRP) and 5 patients showed mild generalized aminoaciduria. None of the 
children had glycosuria. Surprisingly, at first presentation, only 7/24 children had an elevated 
urinary calcium/creatinine ratio. However, these measurements were performed on spot 
urine samples, and patients were polyuric, which in our laboratory can result in inaccuracies 
in the determination of creatinine in urine, as the assay is optimized for higher creatinine 
concentrations. A formal 24-h urine calcium determination would have been more 
informative, but is difficult to obtain in non-toilet trained children without catherization. 
 All patients except for patient 17 had nephrocalcinosis at first presentation, the 
first ultrasound in patient 5 was performed abroad and the report could not be retrieved. 
Patient 17 had a family history of autosomal dominant dRTA (in her mother and 
grandmother) and was screened before the onset of symptoms. In the other children, at the 
moment of diagnosis nephrocalcinosis was reported by the radiologist to be mild (increased 
echogenicity in the borders of the pyramids) in 10 patients, moderate (diffuse increased 
echogenicity of the entire pyramids) or moderate to marked in 4 children and marked 
(homogenous increased echogenicity of the entire pyramids, often in the presence of 
acoustic shadowing) in another 8 patients. Only 3 children developed renal calculi (patient 
10, 19 and 23), none of them required medical intervention. There was no correlation with 
the degree of nephrocalcinosis at first presentation (marked in patient 10 and 23 and mild in 
patient 19). 
 
Treatment 
Treatment with alkali (bicarbonate and/or citrate) was started at a median age of 4 months 
(range 2 weeks – 5 years). Initial alkali prescription was as high as 8.6 mmol bicarbonate 
equivalent/kg/day in some children at the onset of therapy in order to achieve normal plasma 
bicarbonate values. In general, most children had a higher alkali requirement in the first 
years of life, which decreased after the first decade. Moreover, children with mutations that 
encoded part of the vacuolar H+-ATPase (ATP6V1B1 and ATP6V0A4) were prescribed 
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higher alkali doses compared to children with mutations that encode the anion exchanger 1 
(SLC4A1), (figure 4). 
Thiazide diuretics were administered to 3 patients. In patient 8 thiazides were started 
at the age of 2 months and stopped after two years, in patient 9 thiazides were started at the 
age of 1 month and stopped one month later. In both of them, thiazides were started in the 
referring centres. Patient 23 was started at the age of 11 years after two episodes of flank 
pain that resolved after passing concrements, Thiazide treatment was continued into 
adulthood.  
Patient 15 was started on indomethacin by the referring team at the age of 6 months 
because of severe polyuria with the possible diagnosis of renal Fanconi syndrome. After the 
diagnosis of dRTA the indomethacin had been stopped at the age of 2 years, but was 
restarted because of worsening of polyuria. 
 
Clinical features at last follow-up 
Growth parameters 
After the start of alkali treatment, there was a clear improvement in growth parameters in 
most children. Sustained growth retardation, with a height on or below -2 SDS on the most 
recent measurement, was documented in only 3 children, while the overall height SDS had 
improved in all groups. A similar improvement in weight SDS was found (figure 2). There was 
no clear correlation with growth retardation at the most recent follow-up and the age of 
therapy onset (2 months, 9 months and 5.3 years, respectively) or gene mutation 
(ATP6V0A4, SLC4A1 and unknown). One child with sustained growth retardation had a 
normal renal function with an eGFR of 152 mL/min/1.73 m2, the other two had chronic kidney 
disease (CKD) stage 2 with an eGFR of 67 and 70 mL/min/1.73 m2, respectively.  
 
Chronic kidney disease 
Renal insufficiency was found in 9/24 children, all of them had an eGFR of 60-90 
mL/min/1.73 m2, consistent CKD stage 2. There was no clear correlation with renal function 
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and genetic diagnosis: decreased renal function was found in 1/6 patients with mutations in 
ATP6V1B1, in 5/10 patients with ATP6V0A4 mutations, in 1/3 patients with SLC4A1 
mutations and in 2/5 children who had no confirmed genetic diagnosis.  
 
Radiological features 
In 9/24 patients, medullary cysts were reported on the most recent renal ultrasound. The age 
at which the first cysts were noted ranged between 3-17 years. Two out of three patients who 
developed renal calculi had medullary cysts, but there was no correlation with the degree of 
nephrocalcinosis at diagnosis (which was mild in 5 patients with medullary cysts, moderate in 
1 and marked in another 3 patients). Also, there was no clear effect on renal function, which 
was normal in 3 patients with renal cysts while the remaining 6 patients had CKD stage 2. 
Four out of ten patients with ATP6V0A4 mutations developed cysts, all after the age of 10. 
Two out of three patients with mutations in SLC4A1 developed cysts, one was 4 years old 
and the other at the age of 17. No molecular diagnosis could be made in the remaining 3 
patients that developed medullary cysts, all of them were below the age of 10 when the cysts 
were first noted. There was no apparent correlation between the degree of nephrocalcinosis 
and the development of CKD. 
 
Hearing 
Hearing loss was documented in 11 children, including all children with ATP6V1B1 
mutations. The hearing problems were found to be sensorineural in origin in 6 patients, 5 of 
which had documented mutations in ATP6V1B1. In the other child no causative mutations 
were found. Three children were diagnosed with conductive hearing loss. This was attributed 
to recurrent ear infections in 2 of them and improved over time, in the other child no mutation 
was found. Another 2 children were found to have combined sensorineural and conductive 
hearing problems, one of them had a mutation in ATP6V0A4 and the other one in SLC4A1. 
   
Discussion 
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We present clinical data on the follow-up of children with dRTA in a single centre, including 
the available data on genetic analysis. Although the sample size is rather small, this study 
contains valuable data on the long-term follow-up of patients with a rare disease. The 
majority of patients were followed for a long period of time, 20/24 patients were followed for 
at least 5 years and 12/24 patients for at least 10 years. The addition of molecular 
diagnostics enables us to compare the clinical phenotype with the molecular genotype. 
Moreover, the analysis of clinical data informs the prognosis and management of patients 
with this rare disease.  
Lastly, we found 5 mutations that to our knowledge are new to the literature. 
Publication of these will help establishing the diagnosis in other patients found to carry these 
mutations. 
  
Treatment 
The administration of alkali is the cornerstone of treatment of dRTA. Due to a higher 
metabolic rate and protein intake in growing children, they may need relatively higher 
treatment doses than adults when corrected for body weight to maintain a normal pH. This 
was previously reported in a historical study in which 5 children with dRTA were followed  for 
a period of <10 years [7]. Where adults in general require 0.5-1 mEq/kg/d of bicarbonate, this 
can be up to 5-8 mEq/kg in children [1]. The fact that younger children in general need higher 
doses of alkali was confirmed in this study. Moreover, children with mutations interrupting the 
function of the vacuolar H+-ATPase generally needed higher doses of alkali compared to 
those with mutations in SLC4A1 (figure 4) and prescribed doses were typically highest at 
therapy onset. This is in line with the finding that children with mutations in ATP6V0A4 in 
general had a lower blood pH and lower serum bicarbonate levels at diagnosis (figure 3). In 
cases with severe hypokalemia, potassium supplements may also be warranted. In these 
patients, the prescription of potassium citrate or potassium bicarbonate can prove to be an 
elegant way to administer both.  
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Thiazide diuretics are sometimes used to decrease urinary calcium excretion, but 
they can in turn increase the risk of hypokalemia and polyuria and are thus not routinely used 
in our centre. In our cohort of 24 patients, only 3 children developed small calculi and none of 
them needed an intervention. Moreover, urinary calcium excretion is increased in acidosis 
and decreases after the administration of alkali [7,8]. This makes it a good marker for 
adherence to and/or adequacy of treatment, but is no longer reliable after the administration 
of thiazide diuretics. Thus, in our opinion the use of alkali treatment, sometimes with 
additional potassium supplements, is sufficient to treat the majority of children with dRTA. 
The experience with patient 17, in whom routine biochemistries of plasma and urine 
were normal at the age of 12 months, suggests that a clinical diagnosis of dRTA cannot be 
excluded at such a young age in at-risk children and should ideally be established 
molecularly, or, if this not possible, by clinical examination when the system is “stressed” (for 
instance after acid loading or, as in patient 17, during an episode of gastroenteritis with 
intestinal bicarbonate loss). 
 
Associated symptoms 
Interestingly, 16/24 children in this study had features of renal Fanconi syndrome at 
presentation. The latter indicates a proximal tubular dysfunction characterized by low-
molecular weight proteinuria (also referred to as tubular proteinuria), generalized 
aminoaciduria, hyperphosphaturia, glucosuria and increased urinary losses of bicarbonate 
(causing metabolic acidosis). Several other solutes that are reabsorbed in the proximal 
tubule can be lost as well [9,10]. In our cohort, the 16 patients with partial renal Fanconi 
syndrome showed a combination of low-molecular weight proteinuria (measured as urinary 
retinol binding protein/creatinine ratio), increased urinary losses of phosphate (measured as 
TRP) and/or mild generalized aminoaciduria. Metabolic acidosis was obviously found in all 
patients, since this is a key feature of dRTA. However, none of the patients had a full-blown 
renal Fanconi syndrome, since none of them showed glucosuria. In this way, the proximal 
tubulopathy resembles that of Lowe syndrome or Dent disease [11]. After initiation of alkali 
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treatment, the features of renal Fanconi syndrome disappeared in all patients, establishing 
the correct diagnosis of dRTA in some children that had previously been diagnosed with 
renal Fanconi syndrome of unknown etiology. There have been several reports of children 
with dRTA presenting with partial renal Fanconi syndrome (low-molecular weight proteinuria, 
hyperphosphaturia and/or generalized aminoaciduria). As in our study, none of them had 
glucosuria and in all of them the proximal tubulopathy disappeared after treatment onset 
[7,12-14]. The exact mechanism by which dRTA causes proximal tubular damage is 
unknown, but given the similarity of the tubulopathy with Dent Disease/Lowe syndrome it is 
tempting to speculate that this may be due to impairment of similar pathways. Indeed, apart 
from those with unknown mutations the proximal tubulopathy was seen only in children with 
mutations in subunits of the vacuolar ATPase, which is expressed together with CLC-5 (the 
chloride transporter underlying Dent disease) in the lysosomes of the proximal tubule and α-
intercalated cells [15]. However, why this lysosomal dysfunction would improve with 
correction of the acidosis is unclear, and the proximal tubulopathy may just reflect a general 
dysfunction from the acidosis. From a clinical point of view, the key conclusion is to not 
prematurely exclude dRTA as a potential diagnosis in patients with a proximal tubulopathy, 
especially in young children with associated nephrocalcinosis. After correction of the acidosis 
and hypokalemia the abnormal markers of proximal tubular function should be monitored, 
since they will normalize in children with underlying dRTA. 
In our population of 24 children with dRTA, the majority of patients (16 in total) had 
proven mutations in ATP6V1B1 (n=6) and ATP6V0A4 (n=10), interrupting the function of the 
vacuolar H+-ATPase. Both mutations can be associated with sensorineural hearing loss [1]. 
In fact, all 6 patients in our cohort who were found to have ATP6V1B1 mutations also had 
hearing loss. However, this was conductive in origin in one of them and was attributed to 
recurrent ear infections. Only one child with mutations in ATP6V0A4 was diagnosed with 
hearing loss: patient 13 was found to have a combined bilateral sensorineural and unilateral 
conductive hearing loss. Her sister, however, was not noted to have any hearing problems. 
Since both have the same mutation in ATP6V0A4, it remains unclear whether this mutation is 
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in fact causing the hearing loss in patient 13. It has been noted before that hearing loss in 
children with ATP6V1B1 mutations generally presents before the age of 10 years, while 
hearing loss in patients with ATP6V0A4 mutations is often only diagnosed from the second 
decade of life [16,17]. The outcome in our cohort is in line with these findings. It also 
warrants the need for regular hearing examination in patients without any signs of deafness 
at diagnosis, since sensorineural hearing loss can still occur later in life. 
 We present one child (patient 19) with the concomitant occurrence of Southeast 
Asian ovalocytosis and dRTA due to mutations in SLC4A1. The protein encoded by this gene 
is a polypeptide which forms a homodimer, to form the transporter AE1. The first deletion 
found in this patient is c.1199_1225del; p.(Ala400-Ala408del). This is a well-known mutation 
typically causing Southeast Asian ovalocytosis, in general occurring without a renal 
phenotype. Mutant non-functioning polypeptides form heterodimers with the wild type 
polypeptide. The minimal net effect on the transport function of the newly formed protein 
results in the absence of a renal phenotype in presence of a wild type allele. However, this 
patient had a second mutation in her other allele, being c.2102G>A; p.(Gly701Asp). This 
mutation gives rise to a mutant polypeptide that is trapped within the cell (probably in the 
Golgi apparatus), thus causing autosomal recessive dRTA. The presence of both mutations 
in 1 patient (one resulting in a non-functioning polypeptide and the other one resulting in a 
polypeptide being trapped intracellularly) causes autosomal recessive dRTA, while the 
c.1199_1225del mutation alone has been reported not to cause a renal phenotype [18,19]. 
Although very rare, this combination of c.1199_1225del with c.2102G>A has been reported 
before to cause a combination of Southeast Asian ovalocytosis and dRTA [20]. 
 In this study, we found medullary cysts on the most recent renal ultrasound in 37.5% 
of our study population (9/24 patients). The development of medullary cysts in a subset of 
patients with dRTA has been well described [21]. The exact etiology of these cysts remains 
unclear, but again it was hypothesized that this may be caused by hypokalemic nephropathy. 
Besides the ischemic changes, hypokalemic nephropathy is associated with tubular 
hypertrophy and dilatation, which may cause renal cyst formation [22]. However, not all 
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conditions with chronic hypokalemia result in cyst formation. For instance, Bartter syndrome 
is often associated with severe chronic hypokalemia but medullary cysts are only rarely 
reported [23]. Moreover, in our population all patients had developed cysts while they were 
receiving treatment. There was no correlation with the development of medullary cysts and 
the degree of nephrocalcinosis at diagnosis, nor with renal function at last follow-up. The 
development of medullary cysts is thus noted in a subset of patients with dRTA, but the 
clinical consequences remain limited in our cohort. 
  
Conclusion 
In general, the prognosis of dRTA is good when the diagnosis can be made early and if there 
is a good compliance to alkali treatment [2]. In this study, we did not find a correlation 
between the age at therapy onset or gene mutation and stunted growth or renal function. 
Nine patients were found to have CKD stage 2. Deterioration of renal function can be seen in 
patients with dRTA, mainly in those with hypercalciuria and recurrent renal stones, but 
progression into end-stage renal disease is only rarely reported [24]. Growth retardation is 
often noted at diagnosis in children with chronic dRTA and is attributed to chronic metabolic 
acidosis. However, after the initiation of alkaline treatment catch-up growth can be noted 
[2,7] and in this study most children (87.5%) had a height within normal limits for age at last 
follow-up, despite profound failure to thrive at diagnosis in 50% of them (figure 2). Thus, we 
can confirm the general good prognosis of dRTA in children under alkali treatment. 
 In conclusion, we present clinical data on long-term follow-up of 24 children with 
dRTA in a single center, including available data on genetic screening and on 5 novel 
disease causing mutation. All but 1 patient presented with the combination of metabolic 
acidosis and nephrocalcinosis, 16 children had features of proximal tubular dysfunction 
which disappeared after initiation of treatment. The diagnosis of renal Fanconi syndrome 
should be made with care in children with severe metabolic acidosis and nephrocalcinosis at 
a young age; markers of proximal tubulopathy should be followed after initiation of treatment. 
Failure to thrive is often noted at diagnosis, alkali treatment results in improved growth 
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parameters in most children. Although their clinical relevance remains uncertain, medullary 
cysts were found in 6 children and are often reported in patients with dRTA. Also, hearing 
loss is often associated with dRTA, mainly when mutations are documented in ATP6V1B1 or 
ATP6V0A4. In the latter gene, sensorineural deafness often develops in the second decade 
of life, warranting long-term follow-up of hearing in children with dRTA with normal initial 
hearing screening who have mutations in ATP6V1B1, ATP6V0A4 or in whom no mutation 
was found. The basic treatment of dRTA consists in the prescription of alkali, if necessary 
combined with potassium supplementation. Although there was a tendency in children with 
ATP6V1B1 or ATP6V0A4 mutations to present earlier in life and to need higher doses of 
alkali, our study population was rather small and we found no statistical significant correlation 
between gene mutation, age at therapy onset, growth parameters or renal function. Long-
term studies including genetic analysis in a bigger population, including data before and after 
transition into adult care can further elaborate on the effects of early treatment onset and 
gene defect on final height, deterioration of renal function over time and the development of 
nephrocalcinosis with calculi and medullary cysts. 
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Figure 1. Age at onset of alkali treatment. 
 
Boxplot showing the age in months when alkali treatment was first initiated, in the different 
genotypes on the left and of all patients on the right. 
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Figure 2. Height and weight at diagnosis and at most recent follow-up. 
 
Boxplot showing the height SDS (upper panels) and weight SDS (lower panels) at diagnosis 
(left panels) and at most recent follow-up (right panels). In each panel the different genotypes 
are depicted on the left and the mean of all patients is depicted on the right. 
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Figure 3. Blood pH and serum bicarbonate levels at diagnosis. 
 
Boxplot showing blood pH (left panel) and serum bicarbonate (right panel) at diagnosis. In 
each panel the different genotypes are depicted on the left and the mean of all patients is 
depicted on the right. 
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Figure 4. Alkali treatment (equivalent to mmols of bicarbonate/kg/day) at different ages. 
 
Boxplot showing the alkali requirement at the age of 1, 5, 10 and 15 years. The first four 
panels represent the alkali requirement per genotype, the last panel represents the alkali 
requirement in all patients. 
